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Metabolic syndrome (MS) is a complex disorder recognized clinically by the findings of abdominal
obesity, elevated triglycerides, atherogenic dyslipidaemia, elevated blood pressure, high blood
glucose and/or insulin resistance. It is associated with a pro-thrombotic and a pro-inflammatory
state. A growing body of evidence suggests that individuals in the community with moderate
airflow limitation may have co-existing systemic inflammation with this background. Therefore,
we examined a population of 237 patients with metabolic disorder for the concomitant presence
of functional pulmonary involvement, as assessed by FEV1 and FVC impairment. Criteria for the
identification of the MS included 3 or more of the following: waist circumference: (>102 cm in
men,>88 cm in women), triglycerides levels (150 mg/dl), high-density lipoprotein cholesterol
levels (<40 mg/dl in men, <50 mg/dl in women), blood pressure (135/85 mmHg), and fast-
ing glucose levels (>100 mg/dl). 119 subjectswerediagnosedMS.Non-smokers patients suffering
from MS presented lower spirometric values, with a trend to ventilatory restrictive more than
obstructive pattern. Also in smokers patients with MS there was a trend to harmonic decrease
in FEV1 and FVC but not in FEV1/FVC ratio, although the changes did not reach statistical signif-
icance. Mainly abdominal circumference, and also insulin resistance were retained as indepen-
dent predictors of both FEV1 and FVC changes. However, HDL-C was the strongest predictor of
FEV1 and FVC changes, with an inverse association.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Metabolic syndrome (MS) is a cluster of risk factors that
increase the probability to develop type 2 diabetes (T2D)06 20900631; fax: þ39 06
iroma2.it (M. Cazzola).
9 Elsevier Ltd. All rights reservedand cardiovascular disease. The features of MS (abdominal
obesity, atherogenic dyslipidaemia, mild elevated blood
pressure, increased blood glucose concentrations and/or
insulin resistance) are also associated with a pro-throm-
botic and a pro-inflammatory state.1 A growing body of
evidence suggests that individuals in the community with
moderate airflow limitation may have co-existing systemic
inflammation.2 In particular, systemic inflammation is.
Table 1 Demographic and metabolic characteristics of
the population included in the study.
Age 60.11 11.60
Sex 132 M and 105 F
Smoking history 27.82 18.65
Waist circumference (cm) 101.46 11.80
Triglycerides (mg/dl) 159.75 141.40
HDL-C (mg/dl) 48.53 14.11
Fasting glucose (mg/dl) 102.38 18.81
Hypertension (yes/no) 168/70
Insulin resistance (yes/no) 117/121
Table 3 Comparison of PFTs between smokers with MS (65
subjects) and smokers without MS (60 subjects).
Pulmonary
Function Test
MET-SYN No MET-SYN p value
FEV1 (l) 2.62 0.84 2.81 0.80 0.218
FEV1 (% pred) 94.92 18.29 98.02 19.80 0.176
FVC (l) 3.19 0.95 3.45 0.93 0.166
FVC (% pred) 93.35 15.87 97.79 16.98 0.169
FEV1/FVC 0.813 0.065 0.808 0.065 0.411
48 P. Rogliani et al.present also in chronic obstructive pulmonary disease
(COPD), a complex disorder characterized local pulmonary
inflammation in response to inhalation of noxious particles
or toxic gases, especially cigarette smoke.3 Currently there
is growing recognition that the inflammatory response
extends beyond the lung.4 In fact, it is likely that the
inflammation in the lung ‘spills over’ into the systemic
circulation to produce systemic effects such as muscle
wasting, cachexia, atherosclerosis, and cardiac disease
have been associated with COPD.5 Comorbidities are
common in COPD and may become harder to manage when
COPD is present, either because COPD adds to the total
level of disability or because COPD therapy adversely
affects the comorbid disorder.3
It is now accepted that patients with COPD often have
one or more component of the MS, with a slightly lower
frequency in severe COPD.6 However, we still do not know if
individual with MS have an higher risk and incidence to
develop COPD, although it has been reported that diabetes
is independently associated with reduced lung function,
and obesity in T2 diabetic patients could further worsen the
severity of COPD.7
With this background, we investigated a population of
patients with metabolic disorder for the concomitant
presence of pulmonary involvement assessed by ordinary
pulmonary function tests (PFTs).
Methods
Patients
We included in this study 237 subjects (132 males, 105
females) who were consecutively admitted in four months
to the metabolic disorders outpatient office of ourTable 2 Comparison of PFTs between non-smokers with
MS (54 subjects) and non-smokers without MS (58 subjects).
Pulmonary
Function Test
MET-SYN No MET-SYN p value
FEV1 (l) 2.42 0.73 2.90 0.93 0.0051
FEV1 (% pred) 99.92 16.42 107.26 14.88 0.0174
FVC (l) 2.86 0.87 3.44 16.20 0.0037
FVC (% pred) 96.20 15.46 104.43 16.20 0.0082
FEV1/FVC 0.845 0.061 0.844 0.069 0.892university hospital because of suspected MS. All patients
denied suffering from COPD or other identified pulmonary
diseases. The NCEP ATP-III criteria that we used for the
identification of the MS is the association of 3 or more of the
following: waist circumference (>102 cm in men, >88 cm in
women), triglycerides levels (150 mg/dl), high-density
lipoprotein cholesterol (HDL-C) levels (<40 mg/dl in men,
<50 mg/dl in women), blood pressure 130/85 mmHg),
and fasting glucose levels (>100 mg/dl).8 Insulin resistance
was measured with the homeostasis model assessment for
insulin resistance or HOMA-IR (HOMA-IRZ insulin [mU/
mL] glucose [mmol/L]/22.5.9 All patients included in the
present study were in a stable state at distance (minimum 8
weeks) from pulmonary infection or acute bronchitis. All
subjects denied that they have suffered from an episode of
right-heart failure (with peripheral oedema) or acute
respiratory failure. None of them was suffering from
muscular weakness.
Conventional spirometry
FVC and FEV1 were measured with standard spirometric
techniques (Masterlab, Jaeger, Wurzburg, Germany). All
values obtained were related to age and gender and
expressed as percentage of their predicted value.
Statistical analysis
Subjects’ characteristics were summarized as mean and
S.D. for continuous variables and frequency and percentage
for categorical variables. Spearman rank correlation coef-
ficients were estimated between the study variables and
potential confounders including BMI, waist circumference,
triglycerides levels, HDL-C levels, blood pressure, and
fasting glucose levels. Multiple linear regression models
were used to examine the association between waist
circumference, triglycerides levels, HDL-C levels, blood
pressure, and fasting glucose levels (as indicators of MS)
and ventilatory function. Separate regression models with
FVC, FEV1 and FEV1/FVC as the outcome variables, with
waist circumference, triglycerides levels, HDL-C levels,
blood pressure, and fasting glucose levels as predictor
variables, were examined in turn. To exclude the possibility
of confounding by smoking-induced respiratory disease, all
multivariate models were repeated in the subgroup of non-
smokers. All statistical analyses were performed using the
SPSS statistical software version 12.0 (SPSS, Inc., Chicago,
IL, USA).
Table 4 Relationships between metabolic parameters and PFTs observed in subjects affected by MET-SYN (119 subjects).
Spearman’s Rank correlations are indicated.
FEV1 (l) FVC (l) FEV1/FVC
Waist circumference (cm) RhoZ 0.16
pZ 0.07
RhoZ 0.14
pZ 0.12
RhoZ 0.06
pZ 0.49
Triglycerides (mg/dl) RhoZ 0.19
pZ 0.04
RhoZ 0.20
pZ 0.03
RhoZ0.099
pZ 0.31
HDL-C (mg/dl) RhoZ0.36
pZ 0.0003
RhoZ0.39
p< 0.0001
RhoZ 0.10
pZ 0.32
Fasting glucose (mg/dl) RhoZ0.20
pZ 0.20
RhoZ0.16
pZ 0.30
RhoZ0.17
pZ 0.28
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237 subjects were included in the study (132 males, 105
females). 125 of them were smokers (27.2 18.65 pack-
years). 119 subjects were diagnosed MS. Metabolic param-
eters are shown in Table 1. The subjects without MS were
used as unexpected control group.
The comparison of PFTs between non-smoker subjects
with MS (54 subjects) and without MS (58 subjects) showed
that the first group was characterized by a significantly
lower FEV1 (l) (pZ 0.0051), FEV1 (% predicted)
(pZ 0.0174), FVC (l) (pZ 0.0037), and FVC (% predicted)
(0.0082), while no difference was observed regarding the
FEV1/FVC ratio (Table 2).
In contrast, considering smokers with MS (65 subjects)
and smokers without MS (60 subjects), no significant
difference was observed in regard to any PFT (Table 3).
However, the MS group showed lower values of FEV1 and
FVC.
The correlations between metabolic parameters and
PFTs observed in subjects affected by MS are shown in
Table 4. Overall, abdominal circumference and triglycer-
ides were positively associated with FEV1, whereas only
triglycerides were positively associated with FVC. On the
contrary, HDL-C was inversely associated with both FEV1
and FVC. Tables 5 and 6 illustrate the correlations between
metabolic parameters and PFTs observed in smokers and
non-smokers affected by MS, respectively. In smokers,
abdominal circumference was positively associated with
FEV1 and FVC, whereas in non-smokers, triglycerides were
positively associated with FEV1 and FVC. In both groups,
HDL-C was inversely associated with both FEV1 and FVC.Table 5 Relationships between metabolic parameters and PFTs
Rank correlations are indicated.
FEV1 (l)
Waist circumference (cm) RhoZ 0.27
pZ 0.03
Triglycerides (mg/dl) RhoZ 0.03
pZ 0.79
HDL-C (mg/dl) RhoZ0.32
pZ 0.01
Fasting glucose (mg/dl) RhoZ0.30
pZ 0.15In order to predict the presence of a pulmonary
involvement in patients with MS, we developed a stepwise
multiple regression model by considering metabolic vari-
ables (HDL-C, triglycerides, hypertension, abdominal
circumference, insulin resistance, fasting glucose) together
with smoking history. These were inserted in the model as
independent variables to predict FEV1 as dependent vari-
able. The best model is shown. HDL-C, hypertension,
abdominal circumference and insulin resistance were
retained as independent predictors of FEV1, with a R
2 of
0.178 and a p value of 0.0011 (Table 7). The best predictor
of FEV1 was HDL-C (F ratio 11.19). Smoking history was
excluded from the model.
Stepwise multiple regression model was also applied to
predict FVC as a dependent variable. HDL-C, hypertension,
abdominal circumference, triglycerides and insulin resis-
tance were retained as independent predictors, with a R2 of
0.230 and a p value of 0.0003 (Table 8). The best predictor
of FVC was HDL (F-ratio 11.03). Again, smoking history was
excluded from the model.
Discussion
The most important finding of this study is that non-smokers
patients suffering from MS present lower spirometric
values, with a small but harmonic reduction in both FEV1
and FVC with an unchanged FEV1/FVC ratio that suggests
ventilatory restrictive more than obstructive pattern.
Consequently, our data seem to indicate that MS is not
associated with airway obstruction and, likely, with COPD,
at least as it is defined by GOLD guidelines.3 Although we
completely agree that any attempts to impose FEV1 (or theobserved in smokers affected by MS (65 subjects). Spearman’s
FVC (l) FEV1/FVC
RhoZ 0.25
pZ 0.04
RhoZ 0.059
pZ 0.64
RhoZ 0.06
pZ 0.65
RhoZ0.10
pZ 0.45
RhoZ0.37
pZ 0.005
RhoZ0.069
pZ 0.61
RhoZ0.27
pZ 0.19
RhoZ0.39
pZ 0.06
Table 6 Relationships between metabolic parameters and PFTs observed in non-smokers affected by MS (54 subjects).
Spearman’s Rank correlations are indicated.
FEV1 (l) FVC (l) FEV1/FVC
Waist circumference (cm) RhoZ 0.027
pZ 0.88
RhoZ0.003
pZ 0.97
RhoZ 0.15
pZ 0.27
Triglycerides (mg/dl) RhoZ 0.38
pZ 0.0059
RhoZ 0.37
pZ 0.0083
RhoZ0.08
pZ 0.57
HDL-C (mg/dl) RhoZ0.28
pZ 0.06
RhoZ0.29
pZ 0.05
RhoZ 0.23
pZ 0.12
Fasting glucose (mg/dl) RhoZ 0.004
pZ 0.98
RhoZ 0.02
pZ 0.91
RhoZ 0.16
pZ 0.51
50 P. Rogliani et al.ratio of FEV1 to FVC) limits in defining COPD are bound to be
arbitrary and contentious, we must also consider that
according to the current GOLD guidelines, only a FEV1/FVC
ratio lower than 0.7 indicates airflow obstruction, thus
allowing a COPD diagnosis.3 We must highlight that our
definition of restricted spirometric pattern is not
completely adequate, but it is an indication for additional
lung function tests to understand the kind of pulmonary
disorder. In fact, the precise determination of restriction
requires the measurement of total lung capacity (TLC) 10
but also that most patients with restriction on spirometry
have this confirmed when the TLC is measured.11 However,
measuring TLC is unfeasible in large studies as it is time
consuming, expensive, and requires special facilities and
trained technicians.
Our finding fits well with the recent documentation that
the prevalence of MS is independently associated with
restrictive lung impairment.12e14 A cross-sectional study of
159 consecutive nondiabetic elderly persons attending two
social centres showed that restrictive, but not obstructive,
respiratory pattern was associated with MS, at least in older
people, and did not only reflect a limitation of ventilation
due to visceral obesity.12 In fact, restriction was an inde-
pendent correlate of MS, also after adjustment for waist
circumference and body mass index (BMI). Lin et al.13
demonstrated an association between MS and restrictive
lung impairment also after adjustment for age, gender,
BMI, smoking, alcohol drinking, and physical activity.
Recently, Nakajima et al.14 confirmed that impaired
restrictive pulmonary function might be associated with
metabolic disorders and MS and documented a severity
dependent association in an apparently healthy population.
Restriction on spirometry can be related to a variety of
etiologies, including diseases such as muscular weakness,Table 7 Significant independent predictors of FEV1 (l)
selected by stepwise multiple regression analysis in patients
affected by MS (119 subjects). p value of the
modelZ 0.0011.
Variable Cumulative R2 F-Ratio
HDL-C (mg/dl) 0.123 11.19
Hypertension (yes/no) 0.147 3.07
Abdominal circumference
(cm)
0.165 2.91
Insulin resistance (yes/no) 0.178 1.42congestive heart failure, interstitial lung disease, diabetes
mellitus and obesity, all of which can also be associated
with increased limitation and morbidity.15e19 The subjects
examined in our study were not suffering from muscular
weakness, right-heart failure and interstitial lung disease,
whereas diabetes mellitus and obesity were features of MS.
Obesity has been shown to be inversely related to lung
function.20e24 Fasting serum insulin levels are negatively
correlated with FVC and FEV1.
25 Furthermore, insulin
resistance assessed by HOMA and prevalence of T2D are
inversely associated with FEV1 and FVC.
26 Actually, in our
patients, abdominal circumference and also insulin resis-
tance were retained as independent predictors of both FEV1
and FVC.
Surprisingly, HDL-C was the strongest predictor of FEV1
and FVC, with an inverse association that has been
observed both in smokers and in non-smokers. This was
a novel, but unexpected finding, considering that numerous
epidemiological studies have associated HDL-C with an
inverse risk for coronary artery disease,27 whereas reduced
pulmonary function, as assessed by FEV1 and FVC, is asso-
ciated with increased incidences of cardiovascular disease
and death in both smokers and non-smokers.28
The mechanisms underlying this association are
unknown. It must be mentioned that several patients pre-
sented low levels of HDL-C (<40 mg/dl in men, <50 mg/dl
in women) and, consequently, the inverse association
between HDL-C and FEV1 and FVC does not mean high levels
of HDL-C and low levels of FEV1 and FVC. In any case, we
must mention that, based on our reported data, the pres-
ence of lung function impairment itself is not clearly
demonstrated as the changes in lung function possibly
reflect changes in thoracic and abdominal wall compliance.Table 8 Significant independent predictors of FVC (l)
selected by stepwise multiple regression analysis in patients
affected by MS (119 subjects). p value of the
modelZ 0.0003.
Variable Cumulative R2 F-Ratio
HDL-C (mg/dl) 0.147 11.03
Hypertension (yes/no) 0.183 4.90
Abdominal circumference
(cm)
0.200 2.60
Triglycerides (mg/dl) 0.217 1.56
Insulin resistance (yes/no) 0.230 1.55
Metabolic syndrome and pulmonary involvement 51Consequently, although statistically significant, the inverse
association between HDL-C and FEV1 and FVC could not be
expression of a pulmonary involvement.
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